<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02896907</url>
  </required_header>
  <id_info>
    <org_study_id>16D.347</org_study_id>
    <nct_id>NCT02896907</nct_id>
  </id_info>
  <brief_title>Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery</brief_title>
  <official_title>A Pilot Study of Intravenous Ascorbic Acid and Folfirinox in the Treatment of Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies the side effects of ascorbic acid and combination
      chemotherapy in treating patients with pancreatic cancer that has spread to other places in
      the body, has come back, or cannot be removed by surgery. Nutrients found in food and dietary
      supplements, such as ascorbic acid, may improve the tolerability of chemotherapy regimens.
      Drugs used in chemotherapy, such as fluorouracil, irinotecan hydrochloride, and oxaliplatin,
      work in different ways to stop the growth of tumor cells, either by killing the cells, by
      stopping them from dividing, or by stopping them from spreading. Giving ascorbic acid and
      combination chemotherapy may work better in treating patients with pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine safety of intravenous ascorbic acid in combination with fluorouracil,
      irinotecan hydrochloride, leucovorin calcium, and oxaliplatin (FOLFIRINOX) as defined by
      Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 in patients with advanced
      pancreatic cancer.

      SECONDARY OBJECTIVES:

      I. To test feasibility of collecting quality of life (QOL), patient reported outcomes (PRO)
      data and correlative studies on patients with advanced pancreatic cancer.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 18, 2016</start_date>
  <completion_date type="Anticipated">January 1, 2019</completion_date>
  <primary_completion_date type="Actual">March 22, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events as determined by CTCAE version 4.03</measure>
    <time_frame>Up to 28 days after the last treatment</time_frame>
    <description>After 4 patients are enrolled on the study and receive at least one dose of intravenous ascorbic acid, the data will be reviewed. If 2 out of the 4 cannot complete 2 courses of FOLFIRINOX then the study will be halted.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life as defined by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30</measure>
    <time_frame>Baseline to up to 28 days after the last treatment</time_frame>
    <description>Change in quality of life over the six measurement times will be modeled using mixed effects linear regression to account for correlation among repeated measurements from the same subjects. Average change in QoL from baseline to follow-up will be computed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <condition>Recurrent Pancreatic Carcinoma</condition>
  <condition>Stage III Pancreatic Cancer</condition>
  <condition>Stage IV Pancreatic Cancer</condition>
  <condition>Unresectable Pancreatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (FOLFIRINOX, ascorbic acid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1. Patients then receive ascorbic acid IV over 2 hours on days 3, 5, 8, 10 and 12. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (FOLFIRINOX, ascorbic acid)</arm_group_label>
    <other_name>Diaminocyclohexane Oxalatoplatinum</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>61825-94-3</other_name>
    <other_name>[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum</other_name>
    <other_name>[Sp-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum</other_name>
    <other_name>Ai Heng</other_name>
    <other_name>Oxalatoplatin</other_name>
    <other_name>trans-l diaminocyclohexane oxalatoplatinum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (FOLFIRINOX, ascorbic acid)</arm_group_label>
    <other_name>136572-09-3</other_name>
    <other_name>Campto</other_name>
    <other_name>Camptosar</other_name>
    <other_name>Camptothecin 11</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin Calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (FOLFIRINOX, ascorbic acid)</arm_group_label>
    <other_name>1492-18-8</other_name>
    <other_name>3590</other_name>
    <other_name>5-Formyl Tetrahydrofolate</other_name>
    <other_name>5-Formyl-5,6,7,8-tetrahydrofolic Acid</other_name>
    <other_name>5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic Acid</other_name>
    <other_name>Adinepar</other_name>
    <other_name>Calcifolin</other_name>
    <other_name>Calcium (6S)-Folinate</other_name>
    <other_name>Calcium Folinate</other_name>
    <other_name>Calcium N-(p-((((6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamate (1:1)</other_name>
    <other_name>Calfolex</other_name>
    <other_name>Calinat</other_name>
    <other_name>Cehafolin</other_name>
    <other_name>Citofolin</other_name>
    <other_name>Citrec</other_name>
    <other_name>Citrovorum Factor</other_name>
    <other_name>Cromatonbic Folinico</other_name>
    <other_name>Dalisol</other_name>
    <other_name>Disintox</other_name>
    <other_name>Divical</other_name>
    <other_name>Ecofol</other_name>
    <other_name>Emovis</other_name>
    <other_name>Flynoken A</other_name>
    <other_name>Folaren</other_name>
    <other_name>Folaxin</other_name>
    <other_name>Foliben</other_name>
    <other_name>Folinic Acid Calcium Salt Pentahydrate</other_name>
    <other_name>Folix</other_name>
    <other_name>Lederfolin</other_name>
    <other_name>Leucosar</other_name>
    <other_name>N-[4-[[(2-Amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amnio]benzoyl]-L-glutamic Acid</other_name>
    <other_name>Rescufolin</other_name>
    <other_name>Tonofolin</other_name>
    <other_name>Rescuvolin</other_name>
    <other_name>Wellcovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (FOLFIRINOX, ascorbic acid)</arm_group_label>
    <other_name>19893</other_name>
    <other_name>2,4-Dioxo-5-fluoropyrimidine</other_name>
    <other_name>5-Fluoro-2,4(1H, 3H)-pyrimidinedione</other_name>
    <other_name>5-Fluorouracil</other_name>
    <other_name>AccuSite</other_name>
    <other_name>Fluracedyl</other_name>
    <other_name>Fluracil</other_name>
    <other_name>Fluroblastin</other_name>
    <other_name>Ribofluor</other_name>
    <other_name>Ro 2-9757</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (FOLFIRINOX, ascorbic acid)</arm_group_label>
    <other_name>2-(1,2-dihydroxyethyl)-4,5-dihydroxy-furan-3-one</other_name>
    <other_name>33832</other_name>
    <other_name>50-81-7</other_name>
    <other_name>Asorbicap</other_name>
    <other_name>C Vitamin</other_name>
    <other_name>C-Long</other_name>
    <other_name>Ce-Vi-Sol</other_name>
    <other_name>Cecon</other_name>
    <other_name>Cenolate</other_name>
    <other_name>L-Ascorbic Acid</other_name>
    <other_name>Vitamin C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of giving informed consent

          -  Histological diagnosis of adenocarcinoma of the pancreas

          -  Stage IV or recurrent pancreatic cancer by imaging

          -  Locally advanced unresectable pancreatic cancer by National Comprehensive Cancer
             Network (NCCN) criteria

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1

          -  No prior treatment for metastatic disease (prior neo-adjuvant or adjuvant
             chemotherapy, except FOLFIRINOX, chemoradiation or radiation allowed)

          -  White blood count &gt;= 3000

          -  Platelets &gt;= 100,000

          -  Total bilirubin =&lt; 1.5 mg/dl

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 5 X upper limit
             of normal (ULN)

          -  Creatinine &lt; 1.5 mg/dL

          -  Glucose-6-phosphatase deficiency (G6PD) level of 5-14 units/g hemoglobin (Hgb) or
             within institutional standard parameters

          -  All subjects of child producing potential must agree to use contraception or avoidance
             of pregnancy measures while enrolled on study

        Exclusion Criteria:

          -  Other pancreatic cancer histology (islet cell, acinar, neuroendocrine tumors)

          -  Resectable pancreatic cancer

          -  Prior neoadjuvant FOLFIRINOX

          -  Pregnant or lactating females

          -  No clinical ascites (mild ascites on scans permissible)

          -  Central nervous system (CNS) metastasis

          -  Known congestive heart failure, significant ventricular arrhythmias, cirrhosis, grade
             4/5 chronic kidney disease, uncontrolled diabetes

          -  Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic
             therapy

          -  Peripheral neuropathy grade 2 or greater

          -  Any condition, psychiatric or otherwise, that would preclude informed consent,
             consistent follow-up or compliance with any aspect of the study (e.g., untreated
             schizophrenia or other significant cognitive impairment, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Posey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Cancer Center at Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.kimmelcancercenter.org/cancer-center.html</url>
    <description>Sidney Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://hospitals.jefferson.edu/</url>
    <description>Thomas Jefferson University Hospital</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2016</study_first_submitted>
  <study_first_submitted_qc>September 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2016</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Tetrahydrofolates</mesh_term>
    <mesh_term>Formyltetrahydrofolates</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

